Cargando…

The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials

OBJECTIVES: This meta-analysis of randomized controlled trials (RCTs) investigated the usefulness of mesenchymal stromal cells (MSCs) to treat patients with COVID-19. Methods: PubMed, Embase, Ovid MEDLINE, the Cochrane Library, and Clinicaltrials.gov were searched for RCTs published before November...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ching-Yi, Chen, Wang-Chun, Hsu, Chi-Kuei, Chao, Chien-Ming, Lai, Chih-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259515/
https://www.ncbi.nlm.nih.gov/pubmed/35849852
http://dx.doi.org/10.1016/j.jiph.2022.07.001
_version_ 1784741800409300992
author Chen, Ching-Yi
Chen, Wang-Chun
Hsu, Chi-Kuei
Chao, Chien-Ming
Lai, Chih-Cheng
author_facet Chen, Ching-Yi
Chen, Wang-Chun
Hsu, Chi-Kuei
Chao, Chien-Ming
Lai, Chih-Cheng
author_sort Chen, Ching-Yi
collection PubMed
description OBJECTIVES: This meta-analysis of randomized controlled trials (RCTs) investigated the usefulness of mesenchymal stromal cells (MSCs) to treat patients with COVID-19. Methods: PubMed, Embase, Ovid MEDLINE, the Cochrane Library, and Clinicaltrials.gov were searched for RCTs published before November 7, 2021. Only RCTs that compared the clinical efficacy and safety of MSCs with other alternative treatments or placebos in the treatment of patients with COVID-19 were included. RESULTS: Six RCTs were included, in which the MSC and control groups consisted of 158 and 135 patients, respectively. The patients who received MSCs had a significantly lower 28-day mortality rate (7.6% vs 21.5%; OR, 0.18; 95% CI, 0.06–0.52; I(2) = 0%) and significantly higher clinical improvement rate (OR, 6.05; 95% CI, 2.31–15.83; I(2) = 0%) than the controls. The patients who received MSCs were associated with a similar risk of adverse events (AEs) and serious AEs to the control group (AEs: OR, 33; 95% CI, 0.09–1.18; I(2) = 59%; serious AEs: OR, 0.30; 95% CI, 0.02–4.41; I(2) = 53%). CONCLUSIONS: MSC treatment may help to improve the clinical outcomes of patients with COVID-19. In addition, MSC treatment appears to be a safe therapeutic option for patients with COVID-19.
format Online
Article
Text
id pubmed-9259515
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
record_format MEDLINE/PubMed
spelling pubmed-92595152022-07-07 The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials Chen, Ching-Yi Chen, Wang-Chun Hsu, Chi-Kuei Chao, Chien-Ming Lai, Chih-Cheng J Infect Public Health Original Article OBJECTIVES: This meta-analysis of randomized controlled trials (RCTs) investigated the usefulness of mesenchymal stromal cells (MSCs) to treat patients with COVID-19. Methods: PubMed, Embase, Ovid MEDLINE, the Cochrane Library, and Clinicaltrials.gov were searched for RCTs published before November 7, 2021. Only RCTs that compared the clinical efficacy and safety of MSCs with other alternative treatments or placebos in the treatment of patients with COVID-19 were included. RESULTS: Six RCTs were included, in which the MSC and control groups consisted of 158 and 135 patients, respectively. The patients who received MSCs had a significantly lower 28-day mortality rate (7.6% vs 21.5%; OR, 0.18; 95% CI, 0.06–0.52; I(2) = 0%) and significantly higher clinical improvement rate (OR, 6.05; 95% CI, 2.31–15.83; I(2) = 0%) than the controls. The patients who received MSCs were associated with a similar risk of adverse events (AEs) and serious AEs to the control group (AEs: OR, 33; 95% CI, 0.09–1.18; I(2) = 59%; serious AEs: OR, 0.30; 95% CI, 0.02–4.41; I(2) = 53%). CONCLUSIONS: MSC treatment may help to improve the clinical outcomes of patients with COVID-19. In addition, MSC treatment appears to be a safe therapeutic option for patients with COVID-19. The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2022-08 2022-07-07 /pmc/articles/PMC9259515/ /pubmed/35849852 http://dx.doi.org/10.1016/j.jiph.2022.07.001 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Chen, Ching-Yi
Chen, Wang-Chun
Hsu, Chi-Kuei
Chao, Chien-Ming
Lai, Chih-Cheng
The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
title The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
title_full The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
title_fullStr The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
title_full_unstemmed The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
title_short The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
title_sort clinical efficacy and safety of mesenchymal stromal cells for patients with covid-19: a systematic review and meta-analysis of randomized controlled trials
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259515/
https://www.ncbi.nlm.nih.gov/pubmed/35849852
http://dx.doi.org/10.1016/j.jiph.2022.07.001
work_keys_str_mv AT chenchingyi theclinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT chenwangchun theclinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT hsuchikuei theclinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT chaochienming theclinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT laichihcheng theclinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT chenchingyi clinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT chenwangchun clinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT hsuchikuei clinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT chaochienming clinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT laichihcheng clinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials